

Laila C Roisman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1655901/publications.pdf>

Version: 2024-02-01

53
papers

2,147
citations

471509

17
h-index

265206

42
g-index

53
all docs

53
docs citations

53
times ranked

3505
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. <i>Molecular Psychiatry</i> , 2017, 22, 1520-1530.	7.9	449
2	Inquiring into the Differential Action of Interferons (IFNs): an IFN- γ Mutant with Enhanced Affinity to IFNAR1 Is Functionally Similar to IFN- β . <i>Molecular and Cellular Biology</i> , 2006, 26, 1888-1897.	2.3	217
3	Interferon- μ Protects the Female Reproductive Tract from Viral and Bacterial Infection. <i>Science</i> , 2013, 339, 1088-1092.	12.6	197
4	DNA repair of oxidative DNA damage in human carcinogenesis: Potential application for cancer risk assessment and prevention. <i>Cancer Letters</i> , 2008, 266, 60-72.	7.2	179
5	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1128-1137.	1.1	160
6	New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface. <i>Journal of Biological Chemistry</i> , 2000, 275, 40425-40433.	3.4	137
7	A Molecular Basis for NKT Cell Recognition of CD1d-Self-Antigen. <i>Immunity</i> , 2011, 34, 315-326.	14.3	118
8	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. <i>Lung Cancer</i> , 2018, 126, 217-223.	2.0	89
9	Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13231-13236.	7.1	87
10	Mutational Analysis of the IFNAR1 Binding Site on IFN- γ Reveals the Architecture of a Weak Ligand-Receptor Binding-site. <i>Journal of Molecular Biology</i> , 2005, 353, 271-281.	4.2	80
11	N-Methylpurine DNA Glycosylase and OGG1 DNA Repair Activities: Opposite Associations With Lung Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1765-1769.	6.3	53
12	The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96-110. <i>Journal of Neurochemistry</i> , 2014, 128, 196-204.	3.9	46
13	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). <i>Lung Cancer</i> , 2018, 124, 117-124.	2.0	46
14	Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, e81-e84.	1.1	41
15	The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1705-1716.	1.1	38
16	Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	21
17	Optimizing the Binding Affinity of a Carrier Protein. <i>Journal of Biological Chemistry</i> , 2004, 279, 18046-18053.	3.4	19
18	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. <i>Lung Cancer</i> , 2020, 148, 48-54.	2.0	18

#	ARTICLE	IF	CITATIONS
19	The impact of osimertinib™ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. <i>Lung Cancer</i> , 2021, 153, 126-133.	2.0	16
20	Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options. <i>Medicine (United States)</i> , 2022, 101, e28561.	1.0	15
21	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	3.7	13
22	Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa125.	0.7	12
23	Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, 278-286.e1.	2.6	10
24	Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab188.	0.7	9
25	Amyloid Precursor Protein Dimerisation Reduces Neurite Outgrowth. <i>Molecular Neurobiology</i> , 2019, 56, 13-28.	4.0	8
26	Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant. <i>Journal of Thoracic Oncology</i> , 2020, 15, e149-e150.	1.1	8
27	Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). <i>Cancers</i> , 2021, 13, 3630.	3.7	8
28	MA 02.06 BRAF Mutant NSCLC: Correlation with PD-L1 Expression, TMB, MSI and Response to ICPI and Anti-BRAF Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1804-S1805.	1.1	7
29	The crystal structure of amyloid precursor-like protein 2 E2 domain completes the amyloid precursor protein family. <i>FASEB Journal</i> , 2019, 33, 5076-5081.	0.5	7
30	Are we facing a cure in lung cancer? KEYNOTE-001 insights. <i>Annals of Translational Medicine</i> , 2019, 7, S215-S215.	1.7	7
31	Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Drug Investigation</i> , 2022, 42, 185-192.	2.2	7
32	Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
33	Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma. <i>JCO Precision Oncology</i> , 2020, 4, 437-441.	3.0	4
34	Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients. <i>Translational Lung Cancer Research</i> , 2018, 7, S334-S335.	2.8	3
35	Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy. <i>Case Reports in Oncology</i> , 2021, 14, 309-317.	0.7	3
36	Liquid biopsy in the practice of neo-oncology. <i>Journal of Thoracic Disease</i> , 2016, 8, E1279-E1281.	1.4	2

#	ARTICLE	IF	CITATIONS
37	145P Impact of next-generation sequencing on survival in lung cancer. Journal of Thoracic Oncology, 2018, 13, S86-S87.	1.1	2
38	P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study. Journal of Thoracic Oncology, 2018, 13, S665-S666.	1.1	1
39	MA06.05 The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact. Journal of Thoracic Oncology, 2018, 13, S376.	1.1	1
40	P1.04-47 Tumor Mutation Burden Through Hybrid Capture “ Circulating Tumor DNA May Predict Response to Immunotherapy in NSCLC. Journal of Thoracic Oncology, 2019, 14, S459.	1.1	1
41	Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 3918-3920.	1.4	1
42	Non-small cell lung cancer PDL1 >50%”should we go single or combo?. Precision Cancer Medicine, 2020, 3, 7-7.	1.8	1
43	Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer. JTO Clinical and Research Reports, 2020, 1, 100002.	1.1	1
44	P3.01-060 The Clinical Utility of ctDNA Gene Analysis in Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S2224-S2225.	1.1	0
45	P3.02-096 The Interaction Between Mast Cells and Lung Cancer Cells Through Extracellular Vesicles. Journal of Thoracic Oncology, 2017, 12, S2272.	1.1	0
46	P3.03-15 Lung Cancer Regulation of Glucose Metabolic Stress Response. Journal of Thoracic Oncology, 2018, 13, S916.	1.1	0
47	P1.13-33 Ex Vivo 2*2*2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S595.	1.1	0
48	P3.04-11 The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2018, 13, S925-S926.	1.1	0
49	146P The clinical impact of comprehensive cfDNA genomic testing in lung cancer. Journal of Thoracic Oncology, 2018, 13, S87.	1.1	0
50	EP1.12-01 Does PCI Still Have a Role in Limited SCLC?. Journal of Thoracic Oncology, 2019, 14, S1016.	1.1	0
51	Abstract 5394: The clinical impact of multiplex ctDNA gene analysis in lung cancer. , 2017, , .		0
52	Abstract LB-041: Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC). , 2017, , .		0
53	Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPI).. Journal of Clinical Oncology, 2018, 36, 9076-9076.	1.6	0